Alpine Immune Sciences Announces Participation in January Investor Conferences

Rhea-AI Summary

Alpine Immune Sciences, Inc. (NASDAQ: ALPN) announced its participation in two major investor conferences in January 2022. The company will present at the H.C. Wainwright BIOCONNECT Virtual Conference on January 10, 2022, available on demand from 7:00 a.m. ET. The second event is the J.P. Morgan Healthcare Conference on January 13, 2022, at 12:00 p.m. ET. Webcasts will be accessible on the company’s investor relations webpage for 90 days. Alpine focuses on developing innovative immunotherapies for cancer and autoimmune diseases.

Positive

• Participation in two prominent investor conferences can enhance market visibility.
• Webcasts increase accessibility for potential investors and stakeholders.

Negative

• None.

SEATTLE--(BUSINESS WIRE)-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that members of its management team will present at the following investor conferences in January 2022:

H.C. Wainwright BIOCONNECT Virtual Conference
Date: Monday, January 10, 2022
Time: Available on demand beginning 7:00 a.m. ET/4:00 a.m. PT
Event: Company Presentation

J.P. Morgan Healthcare Conference
Date: Thursday, January 13, 2022
Time: 12:00 p.m. ET/9:00 a.m. PT
Event: Company Presentation

Webcasts of the H.C. Wainwright, and J.P. Morgan presentations will be available online in the investor relations section of the company’s website at https://ir.alpineimmunesciences.com/events. A replay of the presentations will be available on the company website for 90 days following the webcast.

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005826/en/

Investor Relations

Alex Sharif

Director, Investor Relations and Corporate Development

Alpine Immune Sciences, Inc

206-788-4545

ir@alpineimmunesciences.com

Media Relations

Kelli Perkins

Red House

Kelli@redhousecomms.com

Source: Alpine Immune Sciences, Inc.

FAQ

When will Alpine Immune Sciences present at the H.C. Wainwright BIOCONNECT Virtual Conference?

Alpine Immune Sciences will present at the H.C. Wainwright BIOCONNECT Virtual Conference on January 10, 2022.

What time is Alpine's presentation at the J.P. Morgan Healthcare Conference?

Alpine's presentation at the J.P. Morgan Healthcare Conference is scheduled for 12:00 p.m. ET on January 13, 2022.

Where can I find the webcasts of Alpine's investor presentations?

The webcasts of Alpine's presentations will be available on the investor relations section of their website for 90 days following the events.

What is the focus of Alpine Immune Sciences?

Alpine Immune Sciences focuses on developing innovative immunotherapies for cancer and autoimmune and inflammatory diseases.